See more : Union Financial Corporation (UFCP) Income Statement Analysis – Financial Results
Complete financial analysis of Race Oncology Limited (RAC.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Race Oncology Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Endomines AB (publ) (ENDO.ST) Income Statement Analysis – Financial Results
- TAKKT AG (TTK.DE) Income Statement Analysis – Financial Results
- D-BOX Technologies Inc. (DBOXF) Income Statement Analysis – Financial Results
- LXP Industrial Trust (LXP-PC) Income Statement Analysis – Financial Results
- Hbis Company Limited (000709.SZ) Income Statement Analysis – Financial Results
Race Oncology Limited (RAC.AX)
About Race Oncology Limited
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.00M | 3.13M | 707.81K | 387.39K | 159.37K | 228.50K | 170.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.61M | 281.20K | 281.20K | 281.20K | 281.20K | 281.20K | 250.87K | 250.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.39M | 2.85M | 426.61K | 106.19K | -121.83K | -52.70K | -80.60K | -250.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 34.72% | 91.03% | 60.27% | 27.41% | -76.44% | -23.06% | -47.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 10.98M | 7.60M | 5.83M | 2.20M | 1.28M | 956.34K | 1.75M | 1.21M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 914.36K | 1.52M | 614.46K | 669.70K | 487.36K | 1.21M | 2.79M | 1.81M | 368.25K | 78.22K | 95.21K | 13.12K |
| Selling & Marketing | 431.23K | 323.29K | 176.56K | 174.26K | 104.06K | 1.09M | 1.08M | 550.89K | 54.35K | 0.00 | 0.00 | 0.00 |
| SG&A | 3.79M | 5.11M | 5.37M | 4.00M | 2.40M | 2.53M | 4.33M | 2.58M | 496.20K | 78.22K | 95.21K | 13.12K |
| Other Expenses | 0.00 | 3.13M | 707.81K | 424.89K | 256.44K | 228.50K | 170.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.77M | 12.71M | 11.20M | 6.19M | 3.68M | 3.48M | 6.08M | 3.79M | 496.20K | 87.75K | 95.21K | 13.12K |
| Cost & Expenses | 17.38M | 12.99M | 11.49M | 6.48M | 3.96M | 3.76M | 6.33M | 4.04M | 496.20K | 87.75K | 95.21K | 13.12K |
| Interest Income | 832.58K | 591.84K | 53.92K | 18.85K | 9.32K | 17.36K | 21.66K | 25.21K | 15.75K | 479.00 | 2.84K | 2.97K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 281.20K | 281.20K | 281.20K | 281.20K | 281.20K | 281.20K | 250.87K | 250.00K | 430.59K | 90.72K | 95.21K | 13.12K |
| EBITDA | -14.20M | -12.78M | -11.63M | -6.45M | -3.72M | -3.61M | -6.23M | -3.93M | 0.00 | 3.45K | 2.84K | -40.15K |
| EBITDA Ratio | -354.78% | -405.37% | -1,583.02% | -1,599.18% | -2,308.56% | -1,523.81% | -3,569.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.38M | -12.99M | -11.49M | -6.48M | -3.96M | -3.76M | -6.33M | -4.04M | -496.20K | -90.72K | -95.21K | -13.12K |
| Operating Income Ratio | -334.22% | -414.35% | -1,622.75% | -1,671.77% | -2,485.00% | -1,646.87% | -3,717.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.44M | 3.06M | 283.95K | -251.52K | -44.97K | -124.79K | -147.61K | -129.38K | 104.70K | -9.05K | 2.84K | -27.03K |
| Income Before Tax | -17.82M | -13.06M | -11.91M | -6.73M | -4.01M | -3.89M | -6.48M | -4.17M | -317.89K | -87.27K | -92.37K | -10.15K |
| Income Before Tax Ratio | -445.18% | -416.60% | -1,682.63% | -1,736.70% | -2,513.22% | -1,701.48% | -3,803.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -4.00M | -3.13M | -707.81K | -387.39K | -159.37K | -228.50K | -170.26K | 0.00 | 112.70K | 3.45K | 2.84K | 2.97K |
| Net Income | -13.82M | -9.92M | -11.20M | -6.34M | -3.85M | -3.66M | -6.31M | -4.17M | -317.89K | -87.27K | -92.37K | -10.15K |
| Net Income Ratio | -345.18% | -316.60% | -1,582.63% | -1,636.70% | -2,413.22% | -1,601.48% | -3,703.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.08 | -0.06 | -0.07 | -0.05 | -0.04 | -0.05 | -0.09 | -0.08 | -0.01 | -0.08 | -0.01 | 0.00 |
| EPS Diluted | -0.08 | -0.06 | -0.07 | -0.05 | -0.04 | -0.05 | -0.09 | -0.08 | -0.01 | -0.08 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 164.50M | 160.72M | 153.31M | 130.96M | 106.59M | 79.84M | 67.40M | 52.73M | 52.69M | 1.09M | 11.00M | 10.01M |
| Weighted Avg Shares Out (Dil) | 164.50M | 160.72M | 153.31M | 130.96M | 106.59M | 79.84M | 67.40M | 52.73M | 52.69M | 1.09M | 11.00M | 10.00M |
Source: https://incomestatements.info
Category: Stock Reports